Assessment of the Safety and Pharmacokinetics of Anidulafungin When Administered With Cyclosporine
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Anidulafungin is a novel antifungal agent of the echinocandin class that is intended for the treatment of invasive fungal disease. It is likely that anidulafungin will be coadministered with cyclosporine. In vitro studies and clinical studies were performed to evaluate the effect of anidulafungin on cyclosporine metabolism and to investigate the safety and pharmacokinetics of anidulafungin when concomitantly administered with cyclosporine. The potential for anidulafungin to inhibit the metabolism of cyclosporine was evaluated by pooled human hepatic microsomal protein fractions in vitro, incubating 3 H‐cyclosporine with different concentrations of anidulafungin. The safety of coadministration and the effects of cyclosporine on the pharmacokinetics of anidulafungin were assessed in a multiple‐dose, open‐label clinical study of 12 healthy volunteers. Subjects received a 200‐mg intravenous loading dose of anidulafungin, followed by a daily 100‐mg intravenous maintenance dose on days 2 through 8. An oral solution of cyclosporine (Neoral oral solution; 100 mg/mL) 1.25 mg/kg was also administered to subjects twice daily on days 5 through 8. In the in vitro study, the addition of anidulafungin had no effect on cyclosporine metabolism by human hepatic microsomal protein fractions. In the clinical study, no dose‐limiting toxicities or serious adverse events occurred. A small increase in anidulafungin concentrations and drug exposure (22%) was observed after 4 days of dosing with cyclosporine and was not considered to be clinically relevant. The results support the concomitant use of anidulafungin and cyclosporine without the need for dosage adjustments of either drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“, and Pneumocystis carinii.(4,5) In vitro studies have shown that anidulafungin is fungicidal against Candida spp.”
BackgroundCompounds active against cell walls of medically important fungi
Hector, R. F. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.1.1 · Cited by 242 · cited 1×
“Cross-links between glucan and chitin provide additional cell wall rigidity.(3) Inhibition of glucan synthesis results in osmotic fragility and cell death.”
BackgroundSafety and tolerability of caspofungin acetate in the treatment of fungal infections
Sable, C. A., Nguyen, B. T., Chodakewitz, J. A., & DiNubile, M. J. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2002.01004.x · Cited by 148 · cited 2×
“Increases in hepatic transaminase levels are reported when caspofungin is coadministered with cyclosporine, which precludes its concurrent use unless the potential benefit outweighs the risk.(12,18) Caspofungin may also interact with tacrolimus, another immunosuppressant agent, resulting in a 20% decrease in tacrolimu…”
Background
Cited by
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
“Coadministration of ciclosporin and anidulafungin has revealed a 22%, albeit not clinically significant, increase in the AUC of anidulafungin after 4 days of concomitant therapy.([140])Micafungin decreases clearance of ciclosporin by 16%; in one study, 5 of 28 (18%) subjects experienced a significant change (>25%) in…”
BackgroundCappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205
Anidulafungin: A new echinocandin with a novel profile
Vazquez, J. A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.010 · Cited by 78
The eagle-like effect of echinocandins: what’s in a name?
Vanstraelen, K., Lagrou, K., Maertens, J., Wauters, J., Willems, L., & Spriet, I. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2013.841543 · Cited by 28
Metadata
- Authors
- Dowell, J. A., Stogniew, M., Krause, D., Henkel, T., & Weston, I. E.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-02
- Volume
- 45
- Issue
- 2
- Pages
- 227-233
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1998714365
- Cited by
- 106
- References
- 4
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of the Safety and Pharmacokinetics of Anidulafungin When Administered With Cyclosporine. https://app.cochat.ai/papers/10.1177/0091270004270146
- The paper
- Dowell, J. A., Stogniew, M., Krause, D., Henkel, T., & Weston, I. E. (2005). Assessment of the Safety and Pharmacokinetics of Anidulafungin When Administered With Cyclosporine. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270004270146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.